Cargando…
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome
Clobazam is the newest medication approved by the US Food and Drug Administration (FDA) for the treatment of Lennox–Gastaut syndrome (LGS) in patients at least 2 years of age, although the medication has been available in countries around the world to treat epilepsy and anxiety disorders for many ye...
Autor principal: | Faulkner, Michele A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467745/ https://www.ncbi.nlm.nih.gov/pubmed/26089675 http://dx.doi.org/10.2147/TCRM.S55930 |
Ejemplares similares
-
Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
por: Leahy, Jennifer T, et al.
Publicado: (2011) -
Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome
por: François, Clément, et al.
Publicado: (2017) -
Lennox-Gastaut syndrome: An overview
por: Ramanathan, Ramnath Santhosh, et al.
Publicado: (2010) -
Treatment of Lennox-Gastaut syndrome: overview and recent findings
por: van Rijckevorsel, Kenou
Publicado: (2008) -
Lennox-Gastaut syndrome: Management update
por: Al-Banji, Muradi H., et al.
Publicado: (2015)